LY3451838
/ Eli Lilly
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
August 18, 2025
Is PACAP the next big thing in migraine therapy?
(PubMed, Cephalalgia)
- No abstract available
Journal • CNS Disorders • Migraine • Pain • ADCYAP1
August 21, 2025
Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine.
(PubMed, Cephalalgia)
- P1, P2 | "However, the difference observed between LY3451838 and placebo among CM patients is similar to the statistically significant difference reported in the recent HOPE trial, which primarily consisted of CM patients. Further clinical research with larger sample sizes is needed to inform on the utility of blocking PACAP in various migraine populations.Trial RegistrationClinicalTrials.gov: NCT03692949 (phase 1); NCT04498910 (phase 2)."
Clinical • Journal • P1 data • P2 data • Preclinical • B Cell Lymphoma • CNS Disorders • Hematological Malignancies • Lymphoma • Migraine • Non-Hodgkin’s Lymphoma • Oncology • Pain • ADCYAP1
January 17, 2023
A Study of LY3451838 in Participants With Migraine
(clinicaltrials.gov)
- P2 | N=38 | Completed | Sponsor: Eli Lilly and Company | Recruiting ➔ Completed | N=120 ➔ 38
Enrollment change • Trial completion • CNS Disorders • Migraine
December 09, 2021
A Study of LY3451838 in Participants With Migraine
(clinicaltrials.gov)
- P2; N=120; Recruiting; Sponsor: Eli Lilly and Company; Trial completion date: Nov 2021 ➔ Sep 2022; Trial primary completion date: Nov 2021 ➔ Sep 2022
Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Migraine
November 19, 2020
A Study of LY3451838 in Participants With Migraine
(clinicaltrials.gov)
- P2; N=120; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • CNS Disorders • Migraine
October 06, 2020
A Study of LY3451838 in Participants With Migraine
(clinicaltrials.gov)
- P2; N=120; Not yet recruiting; Sponsor: Eli Lilly and Company; Trial primary completion date: Dec 2020 ➔ Nov 2021
Clinical • Trial primary completion date • CNS Disorders • Migraine
August 07, 2020
A Study of LY3451838 in Participants With Migraine
(clinicaltrials.gov)
- P2; N=120; Not yet recruiting; Sponsor: Eli Lilly and Company
Clinical • New P2 trial • CNS Disorders • Migraine
March 03, 2020
A Study of LY3451838 in Healthy Participants
(clinicaltrials.gov)
- P1; N=53; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed; N=80 ➔ 53
Clinical • Enrollment change • Trial completion
1 to 8
Of
8
Go to page
1